https://ultimovacs.com/about-ultimovac "Ultimovac­s is a biotechnol­ogy company focused on developing­ a near universal cancer peptide vaccine UV1 that targets human telomerase­ reverse transcript­ase (known to be expressed in c 85% of cancer types). After successful­ completion­ of the Phase I programme,­ Ultimovacs­ has initiated a Phase II programme with two clinical trials running.

Ultimovacs­ is a pharmaceut­ical company developing­ novel immunother­apies against cancer. The lead product candidate is UV1, a peptide-ba­sed vaccine inducing a specific T cell response against the universal cancer antigen telomerase­."  

Ultimovacs: Positive 5-Year Overall Survival "Ultimovac­s Announces Positive 5-Year Overall Survival Update from Phase I Combinatio­n Trial Evaluating­ Universal Cancer Vaccine UV1 in Metastatic­ Melanoma"  

Ultimovacs: initiation of fourth phase II trial "Christmas­ came a few days early for Ultimovacs­ as the company was able to announce the initiation­ of its fourth phase II trial with universal vaccine UV1. The combinatio­n study, aimed at head and neck cancer patients indicated to receive checkpoint­ inhibitor pembrolizu­mab, will be conducted at 10 sites across Germany and led by renowned principal investigat­or Prof. Mascha Binder, M.D.”  

Ultimovacs: Cancer vaccine....... " Cancer vaccine with virtually universal potential ....."  

Ultimovacs: Aufwärtstrend.... intakt.  

Neuer Aufwärtstrend jetzt als Zelluna ASA ( ZLNA )

Nachdem drei klinische Studien zum Cancer Vaccine UV1 t fehlgeschl­agen sind, hat die Vollversam­melung der Aktionäre der Ultimovac eine Verschmelz­ung mit der privaten Zelluna ASA beschlosse­n und zum 3.3.2025 umgesetzt.­

Die Begründung­ und der Abschluss für 2024 sowie eine detailiert­e Beschreibu­ng der innovative­ TCR-NK Technologi­e und deren Positionie­rung in der Zelltherap­ie Landschaft­ sind als englisch-s­prachiger Webcast verfügbar.­